Clinical trials: Anti-PD-1
Cancer of Unknown Primary
PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP
This trial is a single-center, prospective, single-arm Phase II clinical study. The purpose is to evaluate the efficacy and safety of recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and…
- Trial name
- NCT04848597
- Testing
- Recombinant humanized anti-PD-1 monoclonal antibody injection
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fudan University
Recurrent or Metastatic Cervical Cancer
A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
This is a multicenter, open-label, phase II clinical study conducted in China. All subjects will receive AK104 in combination with standard treatment regimens or AK104 alone. The primary end point is safety.
- Trial name
- NCT04868708
- Testing
- AK104, Bevacizumab, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Akeso
HCC, Adjuvant Therapy
Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities.
- Conditions
- HCC, Adjuvant Therapy, Recurrence, Immune Checkpoint Inhibitor
- Trial name
- NCT07379489
- Testing
- PD-1 Inhibitors
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Metastatic Melanoma, Liver Metastases
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to…
- Trial name
- NCT07281924
- Testing
- Nivolumab and Relatlimab, Melphalan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Hepatocellular Carcinoma, Liver Cancer
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
The purpose of this clinical research study is to learn about the safety and effectiveness of cabozantinib and nivolumab in people with hepatocellular carcinoma (HCC).
- Trial name
- NCT05039736
- Testing
- Cabozantinib, Nivolumab
- Sponsor
- M.D. Anderson Cancer Center
HIV Infections
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
The purpose of this study was to evaluate the safety and immunotherapeutic activity of an anti-PD-1 antibody (cemiplimab) in participants with HIV-1 on suppressive combination antiretroviral therapy (cART).
- Trial name
- NCT03787095
- Testing
- Cemiplimab
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Cancer, Solid Tumor
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
The primary purpose of this study is to see if Sym021 is safe and tolerable as monotherapy, in combination with either Sym022 or Sym023, and in Combination with both Sym022 and Sym023 for patients with locally…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03311412
- Testing
- Sym021, Sym022, Sym023
- Where
- 4 sites in United States, Canada
- Volunteers
- 89 people
- Sponsor
- Symphogen A/S
Urothelial Cancer
RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
This is a pilot study of a fixed dose of Pembrolizumab in combination with two different regimens of hypofractionated radiation.
- Trial name
- NCT02880345
- Testing
- PEMBROLIZUMAB, hypofractionated radiation
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Nasopharyngeal Carcinoma, PD-1
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that PD-1 treatment added to salvage surgery could further decrease the rate of disease progression and improve the survival outcome of…
- Conditions
- Nasopharyngeal Carcinoma, PD-1, Surgery
- Trial name
- NCT04778956
- Testing
- Toripalimab, salvage surgery
- Where
- 7 sites in China
- Volunteers
- 218 people
- Sponsor
- Sun Yat-sen University
Glioblastoma Multiforme
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
The purpose of this study is to assess the safety/tolerability/feasibility of pembrolizumab and radiation therapy before surgical resection in patients with recurrent glioblastoma as defined by treatment-related AEs and the…
- Trial name
- NCT04977375
- Testing
- Pembrolizumab, Stereotactic Radiation Therapy, Surgical Resection
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Chirag G. Patil
Melanoma of Skin, Acral Melanoma
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
This is a Phase II clinical trial to evaluate the efficacy and safety of perioperative toripalimab (anti-PD-1) combined with recombinant human endostatin (Endostar) as postoperative adjuvant therapy in patients with clinical…
- Conditions
- Melanoma of Skin, Acral Melanoma, Stage II Melanoma
- Trial name
- FUMS-EDJS2024 (NCT06965231)
- Testing
- Toripalimab combined with Endostar
- Where
- 4 sites in China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Lung Cancer, Breast Cancer
Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
The study aim to investigate the relationship between cutaneous adverse events and quality of life in patients taking immune check point inhibitor or cyclin-dependent kinase (CDK) 4 and 6 inhibitors by two steps.
- Conditions
- Lung Cancer, Breast Cancer, Kidney Cancer, Bladder Cancer
- Trial name
- SkinHealth (NCT05878964)
- Testing
- EQ-5D-5L questionnaire, FACT-G (Functional Assessment of Cancer Therapy - General), FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)
- Where
- Italy
- Volunteers
- 420 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or…
- Trial name
- NCT06449209
- Testing
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide
- Where
- 64 sites in United States, Australia and 3 more
- Volunteers
- 110 people
- Sponsor
- BioNTech SE
Vitiligo, Skin Melanoma
Defining the Role of the Skin Microbiome in Immune-related Adverse Events
The skin microbiome has been implicated in several cutaneous autoimmune pathologies such as psoriasis and atopic dermatitis. However, its role in vitiligo and vitiligo lesions occuring in patients receiving anti-PD-1 for…
- Trial name
- SKINBIOTA (NCT04734704)
- Testing
- skin swabs at lesional and non-lesional sites, skin swabs on skin
- Where
- France
- Volunteers
- 57 people
- Sponsor
- University Hospital, Bordeaux
Non-Small Cell Lung Cancer (NSCLC)
Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
Evaluation of FDG PET/CT to image immunotherapy response in adult thoracic cancer. Compare pre- and post-treatment primary tumor uptake for FDG-PET/CT and correlate with clinical markers of response.
- Trial name
- NCT02608528
- Testing
- [18F]fluoroglucose(FDG)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
MSS, pMMR
Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
The purpose of this study is to evaluate the efficacy and safety of fruquintinib or regorafenib in combination with anti-PD-1 antibody in TKI (fruquintinib or regorafenib)-responded MSS/pMMR metastatic colorectal adenocarcinoma.
- Conditions
- MSS, pMMR, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT04483219
- Testing
- TKI ± anti-PD-1 antibody
- Where
- China
- Volunteers
- 53 people
- Sponsor
- China Medical University, China
Non-small Cell Lung Cancer (NSCLC)
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
NEOMUN is designed as an open-label, single arm, prospective, monocenter, phase II study of pembrolizumab in a neoadjuvant setting in patients with non-small cell lung cancer of Stage II/IIIA suitable for curative intent surgery.
- Trial name
- NEOMUN (NCT03197467)
- Testing
- Pembrolizumab
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- AIO-Studien-gGmbH
Melanoma, Metastatic Melanoma
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
The purpose of this research is to test the safety and effectiveness of the investigational combination of Troriluzole, ipilimumab, and nivolumab, and to learn whether this combination works in treating melanoma that has spread…
- Trial name
- NCT04899921
- Testing
- Ipilimumab, Nivolumab, Troriluzole
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Dana-Farber Cancer Institute
SCLC, Extensive Stage
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
Phase Ib open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with chemotherapy in patients with ES-SCLC.
- Trial name
- NCT05116007
- Testing
- AK112, Etoposide, Carboplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Akeso
Advanced Melanoma
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with…
- Trial name
- NCT05529316
- Testing
- Botensilimab, Balstilimab
- Where
- 51 sites in United States, Belgium and 8 more
- Volunteers
- 150 people
- Sponsor
- Agenus Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.